Allogene Therapeutics, Inc. launched CAR T Together, a first-of-its-kind effort comprised of leading clinical trial investigators who represent the field of clinicians committed to supporting the development of “off-the-shelf” (allogeneic) chimeric antigen receptor T products to make CAR T therapy scalable and more accessible to patients with certain cancers. A new survey of U.S. based academic centers specializing in the administration of CAR T, found that 82% of respondents agreed that CAR T therapies have changed how they manage aggressive cancers, but extensive wait times and manufacturing limitations keep many eligible patients from receiving treatment. While the vast majority of late-stage cancer patients are eligible for CAR T treatment, only half of patients who are eligible for currently FDA approved autologous CAR T therapies receive treatment, according to the survey Of those patients eligible for treatment, 12% were able to receive treatment within one month, with approximately 40% waiting three to six months or longer to receive treatment as their disease worsens.

To improve access bottlenecks, CAR T Together brings together oncologists from preeminent research institutions nationwide who want to inspire collaboration to move cancer treatment options forward, supporting the advancement of science, the development of next-generation therapies and addressing the limitations of current therapies.